Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Cash & Equivalents (2021 - 2025)

Prime Medicine (PRME) has disclosed Cash & Equivalents for 5 consecutive years, with $71.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash & Equivalents fell 39.48% year-over-year to $71.4 million, compared with a TTM value of $71.4 million through Sep 2025, down 39.48%, and an annual FY2024 reading of $182.5 million, up 74.95% over the prior year.
  • Cash & Equivalents was $71.4 million for Q3 2025 at Prime Medicine, up from $53.8 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $200.7 million in Q3 2021 and bottomed at $44.0 million in Q3 2023.
  • Average Cash & Equivalents over 5 years is $114.6 million, with a median of $104.3 million recorded in 2023.
  • The sharpest move saw Cash & Equivalents tumbled 76.11% in 2022, then surged 168.38% in 2024.
  • Year by year, Cash & Equivalents stood at $185.4 million in 2021, then grew by 1.19% to $187.6 million in 2022, then plummeted by 44.41% to $104.3 million in 2023, then skyrocketed by 74.95% to $182.5 million in 2024, then tumbled by 60.87% to $71.4 million in 2025.
  • Business Quant data shows Cash & Equivalents for PRME at $71.4 million in Q3 2025, $53.8 million in Q2 2025, and $91.9 million in Q1 2025.